IFNA1 and COVID-19: This disparity grants IFN-λ an advantage over IFN-α, as an increase in IFN-λ levels, whether endogenous or exogenous, during the later stage of COVID-19 does not trigger hyper-inflammation (known as a cytokine storm) and multi-organ damage associated with IFN-α.